2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Francesco Maura, MD, discusses the challenges of whole-genome sequencing in multiple myeloma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Francesco Maura, MD, an assistant professor and principal investigator of the myeloma genomic lab at Sylvester Comprehensive Cancer Center, discusses the challenges of whole-genome sequencing in multiple myeloma.
The widespread adoption of whole-genome sequencing is unlikely in the United States, says Maura. The technology is expensive and difficult to standardize, Maura explains.
The Pan-Cancer Analysis of Whole Genomes Consortium of the International Cancer Genome Consortium and The Cancer Genome Atlas is working toward reaching a consensus regarding the standardization of whole-genome sequencing, Maura explains. However, these complicated guidelines will require tailoring and additional research over many years, so significant and long-term efforts are needed, Maura adds.
Another challenge of whole-genome sequencing is storage, Maura says. Whole-genome sequencing data for 3 to 4 patients requires approximately 1 terabyte of storage, so utilizing this platform for thousands of patients would require adopting a new approach to cancer genomics and data storage, concludes Maura.
Related Content: